Can a blood test be used to test for minimal residual disease (MRD)?

 

In this week’s video, Dr. Brian G.M. Durie explains how Next Generation Flow testing is sensitive enough to detect one myeloma cell in a one million cells.

BOTTOM LINE:
Whereas MRD-testing is done in the bone marrow, NGF tests may be used to monitor plasma cells in the blood.

Have a question? Submit it to AskDrDurie@myeloma.org

IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to askdrdurie@myeloma.org!

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at infoline@myeloma.org